NCT00265655View on ClinicalTrials.gov

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Satraplatin

Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.

Trial Locations (1)

75204

US Oncology, Dallas

Sponsors

Lead Sponsor

Agennix
All Listed Sponsors
lead

Agennix

INDUSTRY

NCT00265655 - Satraplatin for Patients With Metastatic Breast Cancer (MBC) | Biotech Hunter | Biotech Hunter